In the Claims

1(Original). A compound represented by Formula (I):



(I)

or a pharmaceutically acceptable salt, wherein

S_1, S_2, and S_3 are independently

1. H,
2. -OH,
3. halogen,
4. $-C_1$-C_6alkyl,
5. $-O$-C_1-C_6alkyl optionally substituted with 1, 2 or 3 halogens, or –CN;

R_1 is

1. -(C_1-C_6alkyl)-SO_n-(C_1-C_6alkyl) group, optionally substituted with 1, 2 or 3 substituents; wherein each substituent is independently a halogen, -OH and -CN,
2. –C(O)-O-aryl,
3. –C(O)-NH-aryl,
4. –C(O)-NH-heterocycle or N-oxide thereof,
5. –C(O)-NH-C_1-C_6alkyl,
6. –C(O)-NH-cycloC_3-C_6alkyl,
7. $-C_1$-C_6alkyl, optionally substituted with 1 to 6 halogens and 1 hydroxy,
8. –COOH,
9. $-C_1$-C_6alkyl–COOH,
10. $-O$-C_1-C_6alkyl,
11. –cycloC_3-C_6alkyl,
12. $-C_3$-C_6alkyl-heterocycle,

13. aryl,
14. heterocycle,
15. carbonyl,
16. carbamoyl, or
17. -SO_n-(C_1-C_6alkyl);

each n is independently 0, 1, or 2;

Ar_1 and Ar_2 are each independently an aryl or heterocycle or an N-oxide thereof;

R_2 is

1. Hydrogen,
2. aryl optionally substituted with 1, 2 or 3 substituents selected from halogen,
3. heterocycle optionally substituted with 1, 2 or 3 halogens,
4. -C_1-C_6alkyl optionally substituted with 1, 2 or 3 substituents selected from hydroxy and halogen,
5. -COOH,
6. 1, 2 or 3 halogens,
7. -SO_n-(C_1-C_6alkyl),
8. -N(H)-$S(O)_n$-C_1-C_6alkyl,
9. -O-C_1-C_6alkyl substituents each optionally substituted with 1, 2 or 3 halogens,
10. –C(O)-N(H)-C_3-C_6cycloalkyl, or
11. –C(O)-C_1-C_6alkyl;

R_3 is

1. Hydrogen,
2. -C_1-C_6alkyl optionally substituted with hydroxy, –$S(O)_nC_1$-C_6alkyl, heterocycle, or 1, 2, 3, 4, 5 or 6 halogens,
3. aryl or C_6-C_{12}cycloalkyl optionally substituted with phenyl, -C_1-C_6alkyl, -$S(O)_nC_1$-C_6alkyl, -C(O)-O-C_1-C_6alkyl, –COOH, hydroxy-C_1-C_6alkyl- or 1, 2 or 3 halogens,
4. heterocycle or optionally substituted with 1, 2 or 3 substituents independently selected from phenyl, halogen, C_1-C_6alkyl, hydroxyC_1-C_6alkyl, -COOH, -C(O)-O-C_1-C_6alkyl,
5. amino,
6. -C(O)-O-C_1-C_6alkyl,
7. -C_1-C_6alkyl-O-phenyl optionally substituted with 1, 2 or 3 halogens,

8. -C_1-C_6alkyl-phenyl optionally substituted with 1 or 2 substituents selected from hydroxy and halo,
9. -COOH,
10. Halogen,
11. -SO_n-(C_1-C_6alkyl),
12. -N(H)-$S(O)_n$-C_1- C_6alkyl optionally substituted with 1, 2 or 3 halogen,
13. –N(H)-C(O)-C_1-C_6alkyl,
14. –N(H)-heterocycle optionally substituted with 1, 2 or 3 halogens,
15. –N(H)-aryl optionally substituted with 1, 2 or 3 halogens,
16. –N(H)-C_1-C_6alkyl optionally substituted with 1, 2 or 3 halogens,
17. –C(O)-N(H)-C_1-C_6alkyl optionally substituted with 1, 2 or 3 halogens,
18. -C(O)-NH-C_3-C_6cycloalkyl,
19. -O- C_1-C_6alkyl optionally substituted with 1, 2 or 3 halogens or phenyl optionally substituted with 1, 2, or 3 halogen;

R_4 is

1. H,
2. Halogen,
3. –CN
4. –C_1-C_6alkyl,
5. –O-C_1-C_6alkyl optionally substituted with 1, 2 or 3 halogens,
6. -C_1-C_6alkyl-phenyl with phenyl optionally substituted with halogen, or
7. Oxo.

2(Original). A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein

Ar_1 is pyridine or pyridinone or an N-oxide thereof.

3(Original). A compound according to claim 2, or a pharmaceutically acceptable salt thereof, wherein

Ar_2 is phenyl, oxadiazole or thiadiazole.

4(Original). A compound according to claim 3, or a pharmaceutically acceptable salt thereof, wherein

R_1 is -(C_1-C_6alkyl)-SO_n-(C_1-C_6alkyl); and

R2 is -SO_n-C_1-C_6alkyl.

5(Original). A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein
Ar_1 is phenyl.

6(Original). A compound according to claim 5, or a pharmaceutically acceptable salt thereof, wherein
Ar_2 is phenyl, oxadiazole, thiadiazole, pyridine or pyridinone or an N-oxide thereof.

7(Original). A compound according to claim 6, or a pharmaceutically acceptable salt thereof, wherein
R_1 is -(C_1-C_6alkyl)-SO_n-(C_1-C_6alkyl); and
R2 is -SO_n-C_1-C_6alkyl.

8(Original). A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein
Ar_1 is thiazole or oxazole.

9(Original). The compound according to claim 8, or a pharmaceutically acceptable salt thereof, wherein
Ar_2 is phenyl, pyridine or pyridinone or an N-oxide thereof.

10(Original). The compound according to claim 9, or a pharmaceutically acceptable salt thereof, wherein
R_1 is -(C_1-C_6alkyl)-SO_n-(C_1-C_6alkyl); and
R2 is -SO_n-C_1-C_6alkyl.

11(Original). The compound according to claim 1 of Formula Ia



Ia

or a pharmaceutically acceptable salt thereof, wherein:

Ar_1 is phenyl, pyridine, pyridinone, pyrimidyl, thiophene, thiazole, triazole, tetrazole, oxazole, thiaphendiazole, pyridindiazole, imidazothiazole or quinoxaline or an N-oxide thereof; and

Ar_2 is phenyl, pyridine, pyridinone, oxadiazole or thiadiazole or an N-oxide thereof.

12(Original). A compound according to claim 11, or a pharmaceutically acceptable salt thereof, wherein:

R_2 is phenyl, -COOH, -C_1-C_6alkyl, -C_1-C_6alkoxy, mono or di-halo-C_1-C_6alkoxy, hydroxyC_1-C_6alkyl, or -SO_n-(C_1-C_6alkyl) or 1, 2 or 3 halogens;.

13(Original). A compound according to claim 12, or a pharmaceutically acceptable salt thereof, wherein:

R_3 is Hydrogen, amino, biphenyl, N-(tert-butoxycarbonyl)-4-phenylpyrrolidin-3-yl, N-(tert-butoxycarbonyl)azetidin-3-yl, N-(tert-butoxycarbonyl)pyrrolidin-3-yl, 3-chloro-4-fluorophenyl, 4-chlorophenoxymethyl, 2-chlorophenyl, 4-chlorophenyl, ethoxycarbonyl, furan-2-yl, furan-3-yl, imidazol-2-yl, indan-1-yl, indan-2-yl, 1H-indol-2-yl, 1H-indol-3-yl, 1H-indol-4-yl, 1H-indol-5-yl, 1H-indol-6-yl, 1H-indol-7-yl, isoquinolin-1-yl, isoquinolin-4-yl, isoquinolin-5-yl, isoquinolin-8-yl, isoxazol-3-yl, 3-methoxycarbonylphenyl, 4-methoxycarbonylphenyl, methyl, 1-methyl-1Hpyrazol-3-yl, 1-methyl-1Hpyrazol-4-yl, 1-methyl-1Hpyrazol-5-yl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 2-methylpyridin-5-yl, methylsulfonylmethyl, 2-methylsulfonylphenyl, 3-methylsulfonylphenyl,

4-methylsulfonylphenyl, morpholin-4-ylmethyl, phenyl, pyrazinyl, 1Hpyrazol-3-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, 3-pyridinylmethyl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, quinolin-4-yl, quinolin-5-yl, quinolin-8-yl, 5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl, 5,6,7,8-tetrahydro-5Hbenzo[a][7]annulen-5-yl, 5,6,7,8-tetrahydro-5Hbenzo[a][7]annulen-6-yl, tetrahydrofuran-2-yl, 1,2,3,4-tetrahydronaphthalen-1-yl, 1,2,3,4-tetrahydronaphthalen-2-yl, 1,3-thiazol-2-yl, 1,3-thiazol-5-yl, thiophen-2-yl and thiophen-2-yl.

14(Original). A compound according to claim 11, or a pharmaceutically acceptable salt thereof, wherein:

Ar_1 is thiazole;

Ar_2 is phenyl; and

R_2 is $-SO_2$-C_1-C_6alkyl or halogen or C_1-C_6alkyl optionally substituted with hydroxy or 1-3 halogens.

15(Original). A compound according to claim 14 or a pharmaceutically acceptable salt thereof, wherein:

R_3 is Hydrogen or -C_1-C_6alkyl optionally substituted with hydroxy, $-S(O)_nC_1$-C_6alkyl, or 1-6 halogens.

16(Original). A compound according to claim 11, or a pharmaceutically acceptable salt thereof, wherein

Ar_1 is pyridine or an N-oxide thereof;

Ar_2 is oxadiazole; and

R_2 is

1. -C_1-C_6alkyl optionally substituted with hydroxy, $-S(O)_nC_1$-C_6alkyl, or 1-3 substituents halogens,
2. –N(H)-C(O)-C_1-C_6alkyl,
3. –COOH, or
4. -C(O)-NH-C_3-C_6cycloalkyl.

17(Original). A compound according to claim 16, or a pharmaceutrically acceptable salt thereof wherein:

R_3 is hydrogen.

18(Original). The compound according to claim 1, selected from the group consisting of:

8-(3-{2-(3-chlorophenyl)-4-[4-(methylsulfonyl)phenyl]-1,3-thiazol-5-yl}phenyl)-6-[1-methyl-1-(methylsulfonyl)ethyl]quinoline,
6-[1-methyl-1-(methylsulfonyl)ethyl]-8-{3-[4-[4-(methylsulfonyl)phenyl]-2-(1-oxidopyridin-4-yl)-1,3-thiazol-5-yl]phenyl}quinoline,
6-[1-methyl-1-(methylsulfonyl)ethyl]-8-{3-[4-[4-(methylsulfonyl)phenyl]-2-(1-oxidopyridin-3-yl)-1,3-thiazol-5-yl]phenyl}quinoline,
2-(3-{5-(3-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}phenyl)-4-[4-(methylsulfonyl)phenyl]-1,3-thiazol-2-yl}phenyl)propan-2-ol,
3-{5-(3-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}phenyl)-4-[4-(methylsulfonyl)phenyl]-1,3-thiazol-2-yl}benzoic acid,
2-{5-(3-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}phenyl)-4-[4-(methylsulfonyl)phenyl]-1,3-thiazol-2-yl}propan-2-ol,
6-[1-methyl-1-(methylsulfonyl)ethyl]-8-(3-{2-(3-methyl-1,2,4-oxadiazol-5-yl)-4-[4-(methylsulfonyl)phenyl]-1,3-thiazol-5-yl}phenyl)quinoline,
6-[1-methyl-1-(methylsulfonyl)ethyl]-8-(3-{4-[4-(methylsulfonyl)phenyl]-1,3-thiazol-5-yl}phenyl)quinoline,
N-cyclopropyl-5-(3-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}phenyl)-4-[4-(methylsulfonyl)phenyl]-1,3-thiazole-2-carboxamide,
6-[1-methyl-1-(methylsulfonyl)ethyl]-8-(3-{2-(6-methyl-1-oxidopyridin-3-yl)-4-[4-(methylsulfonyl)phenyl]-1,3-thiazol-5-yl}phenyl)quinoline,
2-[4-(4-chlorophenyl)-5-(3-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}phenyl)-1,3-thiazol-2-yl]propan-2-ol,
6-[1-methyl-1-(methylsulfonyl)ethyl]-8-(3-{2-methyl-4-[4-(methylsulfonyl)phenyl]-1,3-oxazol-5-yl}phenyl)quinoline,
2-{4-(3-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}phenyl)-5-[4-(methylsulfonyl)phenyl]-1,3-thiazol-2-yl}propan-2-ol,
1,1,1-trifluoro-*N*-{5-(3-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}phenyl)-4-[4-(methylsulfonyl)phenyl]-1,3-thiazol-2-yl}methanesulfonamide,
2-[5-(3-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}phenyl)-4-pyridin-3-yl-1,3-thiazol-2-yl]propan-2-ol,
2-[5-(3-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}phenyl)-4-(1-oxidopyridin-3-yl)-1,3-thiazol-2-yl]propan-2-ol,
1-(4-chlorophenyl)-1-{4-(3-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}phenyl)-5-[4-(methylsulfonyl)phenyl]-1,3-thiazol-2-yl}ethanol,

6-[1-methyl-1-(methylsulfonyl)ethyl]-8-(3-{3-[4-(methylsulfonyl)phenyl]thien-2-yl}phenyl)quinoline,
1-(3"-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}-1,1':2',1"-terphenyl-4-yl)ethanone,
2-(3"-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}-1,1':2',1"-terphenyl-4-yl)propan-2-ol,
6-[1-methyl-1-(methylsulfonyl)ethyl]-8-{3-[5-(3-methyl-1,2,4-oxadiazol-5-yl)-1-oxidopyridin-3-yl]phenyl}quinoline,
5-(3-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}phenyl)-3-(3-methyl-1,2,4-oxadiazol-5-yl)pyridin-2(1*H*)-one,
6-[1-methyl-1-(methylsulfonyl)ethyl]-8-(3-{6-[4-(methylsulfonyl)phenyl]imidazo[2,1-*b*][1,3]thiazol-5-yl}phenyl)quinoline,
6-[1-methyl-1-(methylsulfonyl)ethyl]-8-(3-{2-[4-(methylsulfonyl)phenyl]imidazo[1,2-*a*]pyridin-3-yl}phenyl)quinoline
[3-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}-4"-(methylthio)-1,1':2',1"-terphenyl-4'-yl]methanol,
[3-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}-4"-(methylsulfonyl)-1,1':2',1"-terphenyl-4'-yl]methanol,
2-[3-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}-4"-(methylsulfonyl)-1,1':2',1"-terphenyl-4'-yl]propan-2-ol,
3-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}-4"-(methylsulfonyl)-1,1':2',1"-terphenyl-4'-carboxylic acid,
6-[1-methyl-1-(methylsulfonyl)ethyl]-8-(3-{2-[4-(methylsulfonyl)phenyl]-1-oxidopyridin-3-yl}phenyl)quinoline,
8-{3-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]phenyl}-6-[1-methyl-1-(methylsulfonyl)ethyl]quinoline,
6-[1-methyl-1-(methylsulfonyl)ethyl]-8-(3-{4-[4-(methylthio)phenyl]pyridin-3-yl}phenyl)quinoline,
3"-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}-1,1':2',1"-terphenyl-4-carboxylic acid,
2-(3-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}phenyl)-3-[4-(methylsulfonyl)phenyl]quinoxaline,
6-[1-methyl-1-(methylsulfonyl)ethyl]-8-(3-{3-[4-(methylsulfonyl)phenyl]pyrazin-2-yl}phenyl)quinoline,
5-(3-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}phenyl)-6-[4-(methylsulfonyl)phenyl]pyridin-2(1*H*)-one,

1-methyl-5-(3-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}phenyl)-6-[4-(methylsulfonyl)phenyl]pyridin-2(1*H*)-one,
8-(3-{6-methoxy-2-[4-(methylsulfonyl)phenyl]pyridin-3-yl}phenyl)-6-[1-methyl-1-(methylsulfonyl)ethyl]quinoline,
8-(3-{6-(difluoromethoxy)-2-[4-(methylsulfonyl)phenyl]pyridin-3-yl}phenyl)-6-[1-methyl-1-(methylsulfonyl)ethyl]quinoline,
8-(3-{6-[(4-fluorobenzyl)oxy]-2-[4-(methylsulfonyl)phenyl]pyridin-3-yl}phenyl)-6-[1-methyl-1-(methylsulfonyl)ethyl]quinoline,
1-(4-fluorobenzyl)-5-(3-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}phenyl)-6-[4-(methylsulfonyl)phenyl]pyridin-2(1*H*)-one,
5-(4-fluorophenyl)-6-(3-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}phenyl)pyridin-2(1*H*)-one,
5-(4-fluorophenyl)-1-methyl-6-(3-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}phenyl)pyridin-2(1*H*)-one,
8-{3-[3-(4-fluorophenyl)-6-methoxypyridin-2-yl]phenyl}-6-[1-methyl-1-(methylsulfonyl)ethyl]quinoline,
or a pharmaceutically acceptable salt thereof.

19(Original). The compound according to claim 1, of formula Ia:



wherein

R is selected from the group consisting of
Amino
2-biphenyl
3-biphenyl
N-(tert-butoxycarbonyl)-4-phenylpyrrolidin-3-yl
N-(tert-butoxycarbonyl)azetidin-3-yl
N-(tert-butoxycarbonyl)pyrrolidin-3-yl
3-chloro-4-fluorophenyl
4-chlorophenoxymethyl
2-chlorophenyl
4-chlorophenyl
Ethoxycarbonyl
furan-2-yl
furan-3-yl
imidazol-2-yl

indan-1-yl
indan-2-yl
1H-indol-2-yl
1H-indol-3-yl
1H-indol-4-yl
1H-indol-5-yl
1H-indol-6-yl
1H-indol-7-yl
Isoquinolin-1-yl
Isoquinolin-4-yl
Isoquinolin-5-yl
Isoquinolin-8-yl
isoxazol-3-yl
3-methoxycarbonylphenyl
4-methoxycarbonylphenyl
Methyl
1-methyl-1H-pyrazol-3-yl
1-methyl-1H-pyrazol-4-yl
1-methyl-1H-pyrazol-5-yl
2-methylphenyl
3-methylphenyl
4-methylphenyl
2-methylpyridin-5-yl
Methylsulfonylmethyl
2-methylsulfonylphenyl
3-methylsulfonylphenyl
4-methylsulfonylphenyl
morpholin-4-ylmethyl
Phenyl
Pyrazinyl
1H-pyrazol-3-yl
pyridin-2-yl
pyridin-3-yl
pyridin-4-yl
3-pyridinylmethyl
pyrimidin-2-yl
pyrimidin-4-yl
pyrimidin-5-yl
quinolin-4-yl
quinolin-5-yl
quinolin-8-yl
5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl
6,7,8,9-tetrahydro-5H-benzo[a][7]annulen-5-yl
6,7,8,9-tetrahydro-5H-benzo[a][7]annulen-6-yl
Tetrahydrofuran-2-yl
1,2,3,4-tetrahydronaphthalen-1-yl
1,2,3,4-tetrahydronaphthalen-2-yl
1,3-thiazol-2-yl
1,3-thiazol-5-yl
thiophen-2-yl
thiophen-3-yl

20(Original). The compound according to claim 1, selected from the group consisting of:

6-[1-methyl-1-(methylsulfonyl)ethyl]-8-(3-{2-[3-(methylsulfonyl)phenyl]-4-phenyl-1,3-thiazol-5-yl}phenyl)quinoline,
2-[4-(3-chlorophenyl)-5-(3-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}phenyl)-1,3-thiazol-2-yl]propan-2-ol,
2-[4-(4-fluorophenyl)-5-(3-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}phenyl)-1,3-thiazol-2-yl]propan-2-ol,
8-{3-[4-(4-chlorophenyl)-2-quinolin-5-yl-1,3-thiazol-5-yl]phenyl}-6-[1-methyl-1-(methylsulfonyl)ethyl]quinoline,
2-{3-[4-(3-chlorophenyl)-5-(3-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}phenyl)-1,3-thiazol-2-yl]phenyl}propan-2-ol,
2-{3-[4-(3-chloro-4-fluorophenyl)-5-(3-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}phenyl)-1,3-thiazol-2-yl]phenyl}propan-2-ol,
2-{3-[4-[3,4-bis(difluoromethoxy)phenyl]-5-(3-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}phenyl)-1,3-thiazol-2-yl]phenyl}propan-2-ol,
N-{5-(3-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}phenyl)-4-[4-(methylsulfonyl)phenyl]-1,3-thiazol-2-yl}acetamide,
N-{5-(3-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}phenyl)-4-[4-(methylsulfonyl)phenyl]-1,3-thiazol-2-yl}pyridin-4-amine,
2-[5-(3-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}phenyl)-4-pyridin-4-yl-1,3-thiazol-2-yl]propan-2-ol,
2-[5-(3-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}phenyl)-4-(1-oxidopyridin-4-yl)-1,3-thiazol-2-yl]propan-2-ol,
2-[5-(4-chlorophenyl)-4-(3-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}phenyl)-1,3-thiazol-2-yl]propan-2-ol,
2-{3-[4-(4-chlorophenyl)-5-(3-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}phenyl)-1,3-thiazol-2-yl]phenyl}propan-2-ol, and
6-[1-methyl-1-(methylsulfonyl)ethyl]-8-{3-[5-(1*H*-tetraazol-5-yl)pyridin-3-yl]phenyl}quinoline,
or a pharmaceuticaly acceptable salt thereof.

21(Original). The compound according to claim 1, selected from the group consisting of:
6-[1-methyl-1-(methylsulfonyl)ethyl]-8-(3-{5-[4-(methylsulfonyl)phenyl]-1-oxidopyridin-3-yl}phenyl)quinoline,
6-[1-methyl-1-(methylsulfonyl)ethyl]-8-(3-{5-[3-(methylsulfonyl)phenyl]-1-oxidopyridin-3-yl}phenyl)quinoline,
6-[1-methyl-1-(methylsulfonyl)ethyl]-8-(3-{5-[2-(methylsulfonyl)phenyl]-1-oxidopyridin-3-yl}phenyl)quinoline,

6-[1-methyl-1-(methylsulfonyl)ethyl]-8-(3-{2-[4-(methylsulfonyl)phenyl]pyridin-3-yl}phenyl)quinoline,
6-[1-methyl-1-(methylsulfonyl)ethyl]-8-[3-(1-oxido-5-phenylpyridin-3-yl)phenyl]quinoline,
8-{3-[5-(3,5-dichlorophenyl)-1-oxidopyridin-3-yl]phenyl}-6-[1-methyl-1-(methylsulfonyl)ethyl]quinoline,
8-{3-[5-(3,4-dimethoxyphenyl)-1-oxidopyridin-3-yl]phenyl}-6-[1-methyl-1-(methylsulfonyl)ethyl]quinoline,
6-[1-methyl-1-(methylsulfonyl)ethyl]-8-{3-[5-(5-methyl-1,2,4-oxadiazol-3-yl)-1-oxidopyridin-3-yl]phenyl}quinoline,
6-[1-methyl-1-(methylsulfonyl)ethyl]-8-{3-[5-(5-methyl-1,3,4-oxadiazol-2-yl)-1-oxidopyridin-3-yl]phenyl}quinoline,
8-{3-[6-(benzyloxy)-5-(3-methyl-1,2,4-oxadiazol-5-yl)pyridin-3-yl]phenyl}-6-[1-methyl-1-(methylsulfonyl)ethyl]quinoline,
6-[1-methyl-1-(methylsulfonyl)ethyl]-8-(3-{6-[4-(methylsulfonyl)phenyl]-1-oxidopyridin-3-yl}phenyl)quinoline,
6-[1-methyl-1-(methylsulfonyl)ethyl]-8-(3-{5-[4-(methylsulfonyl)phenyl]-1-oxidopyridin-2-yl}phenyl)quinoline,
6-[1-methyl-1-(methylsulfonyl)ethyl]-8-{3-[3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)pyridin-2-yl]phenyl}quinoline,
1-(4-chlorophenyl)-3-(3-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}phenyl)pyridin-2(1*H*)-one,
N-isopropyl-5-(3-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}phenyl)-4-[4-(methylsulfonyl)phenyl]thiophene-2-carboxamide,
6-[1-methyl-1-(methylsulfonyl)ethyl]-8-(1,1':2',1"-terphenyl-3-yl)quinoline,
6-[1-methyl-1-(methylsulfonyl)ethyl]-8-[4"-(methylthio)-1,1':2',1"-terphenyl-3-yl]quinoline,
6-[1-methyl-1-(methylsulfonyl)ethyl]-8-[2'-(5-methyl-1,3,4-oxadiazol-2-yl)-1,1'-biphenyl-3-yl]quinoline,
methyl 3-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}-4"-(methylsulfonyl)-1,1':2',1"-terphenyl-4'-carboxylate,
6-[1-methyl-1-(methylsulfonyl)ethyl]-8-(1,1':4',1"-terphenyl-3-yl)quinoline,
6-[1-methyl-1-(methylsulfonyl)ethyl]-8-(1,1':3',1"-terphenyl-3-yl)quinoline,
2-[5-(3'-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}-1,1'-biphenyl-2-yl)-1,3-thiazol-2-yl]propan-2-ol,
6-[1-methyl-1-(methylsulfonyl)ethyl]-8-[3'-(1-oxidopyridin-4-yl)-1,1'-biphenyl-3-yl]quinoline,

or a phgarmaceutically acceptable salt thereof.

22(Original). The compound according to claim 1, selected from the group consisting of:

6-[1-methyl-1-(methylsulfonyl)ethyl]-8-(3-{4-[4-(methylsulfonyl)phenyl]pyridin-3-yl}phenyl)quinoline,
6-[1-methyl-1-(methylsulfonyl)ethyl]-8-(3-{4-[4-(methylsulfonyl)phenyl]-1-oxidopyridin-3-yl}phenyl)quinoline,
6-[1-methyl-1-(methylsulfonyl)ethyl]-8-(3-{4-[3-(methylthio)phenyl]pyridin-3-yl}phenyl)quinoline,
8-[4',5'-difluoro-4"-(methylthio)-1,1':2',1"-terphenyl-3-yl]-6-[1-methyl-1-(methylsulfonyl)ethyl]quinoline,
8-[4',5'-difluoro-4"-(methylsulfonyl)-1,1':2',1"-terphenyl-3-yl]-6-[1-methyl-1-(methylsulfonyl)ethyl]quinoline,
8-(4"-fluoro-1,1':2',1"-terphenyl-3-yl)-6-[1-methyl-1-(methylsulfonyl)ethyl]quinoline,
6,7-dichloro-2-(3-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}phenyl)-3-[4-(methylsulfonyl)phenyl]quinoxaline,
2-(4-chlorophenyl)-3-(3-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}phenyl)quinoxaline,
2-{4-[3-(3-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}phenyl)quinoxalin-2-yl]phenyl}propan-2-ol,
2-[3,4-bis(difluoromethoxy)phenyl]-3-(3-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}phenyl)quinoxaline,
4-[3-(3-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}phenyl)quinoxalin-2-yl]benzoic acid,
N-cyclopropyl-4-[3-(3-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}phenyl)quinoxalin-2-yl]benzamide,
2-(3-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}phenyl)-3-(4-methylphenyl)quinoxaline,
2-(3-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}phenyl)-3-phenylquinoxaline,
2-(4-fluorophenyl)-3-(3-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}phenyl)quinoxaline,
2-{4-[3-(3-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}phenyl)pyrazin-2-yl]phenyl}propan-2-ol,
6-[1-methyl-1-(methylsulfonyl)ethyl]-8-(3-{3-[4-(methylthio)phenyl]pyrazin-2-yl}phenyl)quinoline,

8-{3-[3-(4-fluorophenyl)pyrazin-2-yl]phenyl}-6-[1-methyl-1-(methylsulfonyl)ethyl]quinoline,
8-(3-{2-(2-ethylpyridin-4-yl)-4-[4-(methylsulfonyl)phenyl]-1,3-thiazol-5-yl}phenyl)-6-[1-methyl-1-(methylsulfonyl)ethyl]quinoline,
2-(4-{5-(3-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}phenyl)-4-[4-(methylsulfonyl)phenyl]-1,3-thiazol-2-yl}phenyl)propan-2-ol,
or a pharmaceutically acceptable salt thereof.

23(Original). A pharmaceutical composition comprising a therapeutically effective amount of the compound according to claim 1 or a pharmaceutically acceptable salt thereof; and

a pharmaceutically acceptable carrier.

24(Original). The pharmaceutical composition according to claim 18, further comprising a Leukotriene receptor antagonist, a Leukotriene biosynthesis inhibitor, an M2/M3 antagonist, a corticosteroid, an H1 receptor antagonist or a beta 2 adrenoceptor agonist.

25(Original). The pharmaceutical composition according to claim 18, further comprising a COX-2 selective inhibitor, a statin, or an NSAID.

26. Canceled.

27. Canceled.

28. Canceled.